Related Experiment Video
Updated: May 25, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Evidence-based hypertension treatment in patients with diabetes
Mariana Garcia-Touza1, James R Sowers1
1From the Division of Endocrinology, Diabetes & Metabolism, Department of Internal Medicine, University of Missouri ; 1 the Department of Medical Physiology and Pharmacology ; 2 and the Harry S. Truman VA Medical Center, Columbia, MO 3.
Insights
Hypertension in diabetes patients requires careful blood pressure management. A goal of 135/85 mmHg may balance reducing stroke and coronary artery disease risks, based on recent trial data.
Area of Science:
- Cardiology
- Endocrinology
- Nephrology
Background:
- Diabetes and impaired glucose tolerance significantly increase risks for hypertension, cardiovascular disease, and renal disease.
- Recent clinical trials are evolving hypertension treatment goals for diabetic patients.
- Previous trials like ACCORD BP and INVEST did not show additional cardiovascular benefits at lower blood pressure targets.
Purpose of the Study:
- To evaluate the optimal blood pressure goal for patients with diabetes.
- To analyze the impact of different blood pressure targets on cardiovascular and stroke events in diabetic populations.
Main Methods:
- Review of recent clinical trials including ACCORD BP and INVEST.
- Post hoc analysis of patient data from the International Verapamil-Trandolapril Study (INVEST).
- Examination of evidence regarding blood pressure reduction and its effect on stroke and coronary events.
Main Results:
- Lowering systolic blood pressure below 130 mmHg reduced stroke events but not coronary disease events in diabetic patients.
- The Action to Control Cardiovascular Risk in Diabetes-BP Arm (ACCORD BP) trial showed no additional cardiovascular benefit at a mean systolic BP of 119 mmHg.
- The International Verapamil-Trandolapril Study (INVEST) found no additional cardiovascular risk reduction at BP <130/80 mmHg.
Conclusions:
- The precise blood pressure goal for diabetic patients remains under investigation.
- A blood pressure goal of 135/85 mmHg is proposed as a reasonable compromise.
- This target may offer a balance in reducing composite stroke and coronary artery disease events.
Abstract:
Both impaired glucose tolerance and diabetes are associated with substantially increased prevalence of hypertension, cardiovascular and renal disease. The goal for hypertension treatment in diabetic patients is in evolution, because of recent clinical trials. For example, the results of the recent Action to Control Cardiovascular Risk in Diabetes-BP Arm (ACCORD BP) trial failed to show an additional benefit on cardiovascular event reduction at a mean systolic BP of 119 mm Hg. A post hoc analysis of 6,400 patients with type 2 diabetes from the International Verapamil-Trandolapril Study (INVEST) also failed to show additional cardiovascular risk reduction among patients who achieved a BP <130/80 mm Hg. While the evidence fails to support a lower BP goal to reduce coronary events, there was a risk reduction in stroke events both in ACCORD and the Appropriate Blood Pressure Control in NIDDM (ABCD) trial. A number of other clinical trials also demonstrate that when systolic pressures fall to less than 130 mm Hg, a reduction in stroke but not coronary disease events occurs. Thus, the precise BP goal for diabetic patients remains unresolved. We would posit that a BP goal of 135/85 mm Hg may be a reasonable compromise when viewing the impact of BP reduction on composite stroke and coronary artery disease in extant trials.
Related Concept Videos
Hypertension IV: Drug Therapy and Lifestyle Modifications
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Hypertension V: Nursing Management
Hypertension III: Clinical Manifestations and Diagnostic Studies
Antihypertensive Drugs: Action of Diuretics
Diabetic Nephropathy